MAPT and Alzheimer disease: It is noteworthy that tau pathology correlates well with clinical manifestations in AD patients, and therefore, targeting tau by therapeutic means is believed to be a rational approach to prevent neurodegeneration and cognitive impairments in AD patients [22,23,24].